Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

BackgroundSignificant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD).ObjectiveTo assess the long-term safety and efficacy of dupilumab in patients with AD.MethodsThis ongoing, multicenter, open-label extension study (NCT01949311) evaluated long-term dupilumab treatment in adults who had previously participated in phase 1 through 3 clinical trials of dupilumab for AD. This analysis examined patients given...